EMH
0.38
76.7%
C7A
0.002
-50%
DTM
0.055
66.7%
BOC
0.6
-47.8%
SRL
6.62
56.5%
TR2
0.395
-35.2%
CLE
0.065
54.8%
1TT
0.002
-33.3%
CBE
0.15
53.1%
BLZ
0.002
-33.3%
BIT
0.003
50%
LNU
0.002
-33.3%
EXR
0.063
50%
M2M
0.012
-29.4%
M2R
0.003
50%
MGU
0.005
-28.6%
TGN
0.225
50%
EZZ
1.7
-28.1%
MTM
1.02
48.9%
VMM
0.98
-26.9%
TNC
0.605
47.6%
PGY
0.003
-25%
AUR
0.023
43.8%
KOB
0.055
-23.6%
SRJ
0.017
41.7%
FMR
0.26
-21.2%
ZNC
0.115
40.2%
BOA
0.027
-20.6%
AEU
0.335
39.6%
AUG
0.035
-20.5%
EQR
0.064
39.1%
OEL
0.004
-20%
SKM
0.285
39%
VEN
0.004
-20%
DGR
0.025
38.9%
OCT
0.037
-19.6%
HIQ
0.025
38.9%
L1M
0.031
-18.4%
PTX
0.074
37%
DKM
0.14
-17.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts